That's a really important question, and it's great that you're digging into the details of your diagnosis and treatment options.
Vyndamax (tafamidis) is FDA-approved specifically for transthyretin amyloid cardiomyopathy (ATTR-CM), which includes both hereditary and wild-type (non-hereditary) ATTR amyloidosis affecting the Show Full Answer
That's a really important question, and it's great that you're digging into the details of your diagnosis and treatment options.
Vyndamax (tafamidis) is FDA-approved specifically for transthyretin amyloid cardiomyopathy (ATTR-CM), which includes both hereditary and wild-type (non-hereditary) ATTR amyloidosis affecting the heart.
A negative PYP scan does complicate things. A PYP scan is typically used to identify ATTR-CM, and a negative result may suggest the amyloid deposits in your heart are not ATTR type — or that cardiac involvement is minimal or absent. A positive Congo Red biopsy confirms amyloid is present, but it doesn't tell you the type on its own — that requires fibril typing to determine whether it's ATTR, AL, or another type.
Bilateral carpal tunnel syndrome (CTS) and peripheral neuropathy (PN) are recognized features of ATTR amyloidosis, but Vyndamax is specifically indicated for the cardiac manifestation, not neuropathy.
For neuropathy-predominant ATTR, other medications like vutrisiran (Amvuttra) or patisiran (Onpattro) are FDA-approved options.
Given the complexity of your presentation — negative PYP, positive biopsy, CTS, and PN — this is really a conversation worth having closely with an amyloidosis specialist, as fibril typing results would be key to determining the right treatment path.
May 13
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
